drugset
drugset / Trial / NCT01655849

Phase 2 Efficacy Trial of Z160 in Lumbosacral Radiculopathy

NCT01655849 ↗

Phase 2 Completed 141 enrolled Zalicus
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will compare Z160 and placebo in patients with Lumbosacral Radiculopathy for safety and efficacy for a period of 6 weeks.

Timeline

Start
2012-08
Primary completion
2013-10
Completion
2013-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Z160 Small molecule 375 mg —

Indications

radiculopathy